The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of ...

Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.

An experimental drug GSK licensed from Hansoh Pharma has succeeded in a late-stage study in China, boosting the outlook for a therapy the British pharmaceutical company has already advanced into a ...

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions ...

Drug developers focusing on either disease area made up more than 40% of the number of biotech companies and amount raised so ...

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

The acquisition by royalty management company Zymeworks follows a "strategic review" triggered by the failure of a drug for a ...

The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side ...

Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it ...

The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of ...